Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

187.86
+9.535.34%
Post-market: 187.860.00000.00%17:43 EST
Volume:365.17K
Turnover:68.84M
Market Cap:7.05B
PE:-97.39
High:192.94
Open:179.89
Low:179.89
Close:178.33
52wk High:200.00
52wk Low:49.00
Shares:37.51M
Float Shares:19.96M
Volume Ratio:1.41
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9290
EPS(LYR):-1.1836
ROE:-32.30%
ROA:-21.22%
PB:25.71
PE(LYR):-158.72

Loading ...

Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach

Simply Wall St.
·
Feb 02

Belite Bio Showcases Phase 3 Tinlarebant Results at Asia-Pacific Academy of Ophthalmology Congress

Reuters
·
Jan 29

Belite Bio Price Target Maintained With a $185.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 28

U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth

Reuters
·
Jan 28

H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Jan 28

Belite Bio Completes Enrollment in the Dragon Ii Clinical Trial of Tinlarebant for Stargardt Disease (Stgd1)

THOMSON REUTERS
·
Jan 27

Belite Bio Inc - to File Nda With FDA in 1H 2026

THOMSON REUTERS
·
Jan 27

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

GlobeNewswire
·
Jan 27

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Belite Bio, Bank of Marin Bancorp

Reuters
·
Jan 27

BUZZ-Belite Bio climbs as BofA starts coverage with 'buy' rating

Reuters
·
Jan 26

BofA Securities Initiates Coverage on Belite Bio With Buy Rating, $195 Price Target

MT Newswires Live
·
Jan 26

Belite Bio Inc : Bofa Global Research Initiates Coverage With Buy Rating and Price Objective $195.00

THOMSON REUTERS
·
Jan 26

Belite Bio Initiated at Buy by B of A Securities

Dow Jones
·
Jan 26

U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies

Reuters
·
Jan 26

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arrowhead Pharmaceuticals (ARWR) and Alector (ALEC)

TIPRANKS
·
Jan 21

Belite Bio Initiated at Overweight by Morgan Stanley

Dow Jones
·
Jan 06

Belite Bio Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $191

THOMSON REUTERS
·
Jan 06

Morgan Stanley Initiates Belite Bio at Overweight With $191 Price Target

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Belite Bio Inc : Benchmark Raises Target Price to $187 From $132

THOMSON REUTERS
·
Dec 03, 2025